• Wondering if West Pharmaceutical Services at around US$306 is priced for perfection or leaving something on the table for new investors? This article walks through what the current market price might be saying about value.
• The stock has delivered returns of 11.8% over the last 7 days, 25.8% over the last 30 days, 10.8% year to date and 43.2% over the last year. However, the 3 year and 5 year returns of negative 14.6% and negative 5.7% show a very different experience for anyone who held through the longer term.
• These moves have put West Pharmaceutical Services back on many watchlists, especially as investors reassess where they want exposure within the broader life sciences tools and services space. At the same time, coverage has focused on how the company fits into long term themes such as drug delivery, medical devices and outsourced manufacturing capacity for healthcare customers.
• Despite that mix of recent gains and longer term setbacks, the Simply Wall St valuation model currently gives West Pharmaceutical Services a value score of 0 out of 6. The next sections will break down how that result compares across different valuation approaches and introduce an even richer way to think about what the stock is really worth by the end of the article.

West Pharmaceutical Services scores just 0/6 on our valuation checks. See what other red flags we found in the full valuation breakdown.

Approach 1: West Pharmaceutical Services Discounted Cash Flow (DCF) Analysis

A Discounted Cash Flow, or DCF, model starts by projecting a company’s future cash flows and then discounts those back to today using a required rate of return. The result is an estimate of what the business might be worth based purely on those projected cash flows.

For West Pharmaceutical Services, the latest twelve month Free Cash Flow is about $364.4 million. Analysts and extrapolations point to projected Free Cash Flow rising to $630 million by 2029, with a series of annual estimates between 2026 and 2035 generated using a 2 Stage Free Cash Flow to Equity approach. All of these cash flows are assessed in $ and then discounted back to the present.

On this basis, the DCF model produces an estimated intrinsic value of about $196 per share. Compared with a recent share price around $306, this suggests the stock is about 56.2% above the model’s fair value estimate, which screens as clearly expensive on this method.

Result: OVERVALUED

Our Discounted Cash Flow (DCF) analysis suggests West Pharmaceutical Services may be overvalued by 56.2%. Discover 54 high quality undervalued stocks or create your own screener to find better value opportunities.

Approach 2: West Pharmaceutical Services Price vs Earnings

For profitable companies, the P/E ratio is a useful way to connect what you pay for each share with the earnings that support it. Higher growth expectations and lower perceived risk usually justify a higher P/E, while slower growth and higher risk tend to line up with a lower, more conservative multiple.

West Pharmaceutical Services currently trades on a P/E of about 39.9x. That is above the Life Sciences industry average P/E of roughly 34.2x, and also above the peer average of about 30.0x. On simple comparisons, the shares are priced at a premium to both the broader industry and closer peers.

Simply Wall St’s Fair Ratio for West Pharmaceutical Services is 20.5x. This is a proprietary estimate of what the P/E might be given factors such as earnings growth, industry, profit margins, market cap and risk profile. Because it blends these company specific inputs rather than relying only on broad group averages, the Fair Ratio can be a more tailored yardstick than a straight peer or industry comparison. Set against the current P/E of 39.9x, the Fair Ratio points to the shares trading materially above that tailored level.

Result: OVERVALUED

P/E ratios tell one story, but what if the real opportunity lies elsewhere? Start investing in legacies, not executives. Discover our 18 top founder-led companies.

Upgrade Your Decision Making: Choose your West Pharmaceutical Services Narrative

Earlier the article mentioned that there is an even better way to think about valuation. This is where Narratives come in, giving you a simple way to write the story you believe about West Pharmaceutical Services, translate that story into revenue, earnings and margin assumptions, and link those forecasts to a fair value that can be compared directly with the current share price.

A Narrative on Simply Wall St, available on the Community page used by millions of investors, connects the company’s role in areas like GLP 1 exposure, higher value components, contract manufacturing or SmartDose asset sales to explicit numbers such as revenue of US$3.6b, profit margins of 19.0%, earnings of US$675.2m, a future P/E of 42.7x and a fair value around US$338.6. It then updates automatically when fresh news or earnings arrive.

One investor might build a more bullish West Pharmaceutical Services Narrative closer to the US$350 price target, focusing on margin resilience, higher value components and automated delivery capacity. Another might sit nearer the US$260 target and lean on risks such as HVP demand constraints, tariffs, contract shifts and restructuring. By setting up both Narratives side by side you can quickly see which story you believe, how that flows through to fair value and how it stacks up against today’s price to help you decide whether the stock appears appealing or stretched for your own portfolio.

Do you think there's more to the story for West Pharmaceutical Services? Head over to our Community to see what others are saying!

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.